New Zealand government acts to reduce reimbursement waiting list

15 May 2017
new-zealand

The New Zealand government has announced an additional investment of NZ$60 million ($42 million) towards new medicines.

The news was welcomed by Medicines New Zealand, the trade group for the country’s pharmaceutical industry, which has complained of an unduly slow process for decisions on reimbursement.

Last week, the group used its annual report to draw attention to the fact that the list of medicines awaiting a decision from New Zealand’s Pharmaceutical Management Agency, or PHARMAC, had risen from 81 to 94 during 2016.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical